Peter Laveran is a U.S. corporate partner who recently spent more than a decade in Covington's London office and is a vice chair of the firm’s Corporate Group. His broad-based transactional practice is largely international and he has particular transactional experience in the life sciences and media and communications industries. Peter focuses on domestic and complex cross-border acquisitions and divestitures for private equity investors and emerging and mature companies headquartered in the U.S., Europe, and Asia, including Altice, Bayer AG GlaxoSmithKline, Indivior, Itochu, Magticom, Meda AB, Merck & Co. Inc., and Stagecoach Group PLC.

Peter led the Covington team advising Altice in its $9.1 billion acquisition of Suddenlink and the $1 billion co-investment by funds advised by BC Partners and Canada Pension Plan Investment Board in Cablevision Systems Corporation; Bayer AG on its divestitures of the Coppertone sun care business and the Dr. Scholl’s foot care business; Meda AB in in all of its significant U.S. acquisition and divestiture activity in recent years, including the acquisitions of Acton Pharmaceuticals, MidNite, and a collection of women’s health products from Jazz Pharmaceuticals; Indivior in its demerger from Reckitt Benckiser; Itochu in the sale of PrimeSource Building Products, Inc. to Platinum Equity; funds managed by HealthpointCapital, LLC in the merger of Scient'x Groupe SAS with Alphatec Holdings, Inc.; and Magticom in its acquisition of retail and corporate ISP cable assets from Caucasus Online LLC.

Peter also has experience with joint ventures, strategic alliances, non-controlling venture capital and private equity investments, and other corporate finance matters including international capital raising activities in London. His experience includes advising multi-national companies on the planning and development of European distribution structures and other commercial arrangements, and he has directed global post-closing merger integration efforts for clients in over 75 jurisdictions. Peter has held leadership roles in Covington’s Middle East, Indian, and African practices.

Technology equity markets took a sharp turn in the last two months of Q1 2022, with S&P Technology Index reaching to over 18% in the red in mid-March, before closing the quarter at 7% off.  In the last month, across all sectors, Russia’s attack on Ukraine has rattled markets and dented investor appetite amid increased volatility and uncertainty.  The decline in valuations is being impacted by the combined headwinds of rising inflation and interest rates, as well as geopolitical uncertainty. 

Russia’s invasion of Ukraine triggered an unprecedented phenomenon: global technology firms responded to the invasion by suspending or terminating business operations, effectively self-sanctioning beyond regulatory requirements, often at great expense to bottom lines.  This trend will likely continue – in 2022 decisions about where to invest and who to accept investment from will be driven by ethical concerns, as well as the shifting geopolitical risks.  However, as we will see in this article, many tech businesses struggle to fully abandon their presence in Russia.

This article highlights some of the ways in which the Ukraine crisis is changing tech M&A.

Expanded scope of Due Diligence

As tech companies embark on M&A deals, proactive and effective risk management will be more essential than ever.  Enhanced focus on these issues is likely to translate to expansion of transaction timelines.

Continue Reading Ukraine Crisis:  Changing M&A Transactions for Technology Companies